UCB stock: Kygevvi approval meets fresh BIMZELX evidence
Published on 11/14/2026 at 12:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSRegulatory progress and clinical evidence
- Kygevvi received European Union approval on November 13, 2026, for thymidine kinase 2 deficiency.
- UCB reported Week 24 BE BOLD results for BIMZELX in psoriatic arthritis on November 9, 2026.
- The company presented the findings against risankizumab at the 2026 ACR Convergence.
UCB added a European regulatory milestone and fresh clinical evidence to its investor agenda during the week of November 9-13, 2026. On November 13, the European Union approved Kygevvi for thymidine kinase 2 deficiency, according to Pharmaphorum.
Kygevvi combines doxecitine and doxribtimine and is intended for adults and children with genetically confirmed TK2d. The authorization gives UCB a treatment in a narrowly defined rare-disease market and expands its commercial portfolio in Europe.
BIMZELX extends clinical lead
On November 9, UCB announced Week 24 findings from the Phase 3b BE BOLD study of BIMZELX in active psoriatic arthritis. In the company's press release, ACR50 responses at Week 24 were 54.9 percent for bimekizumab and 43.8 percent for risankizumab. UCB said the full results were presented at the 2026 ACR Convergence.
The study enrolled 553 adults and compared BIMZELX with risankizumab in a randomized Phase 3b setting. The clinical advantage came with a safety consideration: the company reported more Candida infections with bimekizumab.
Trading context for investors
UCB stock last traded at 296.85 euros on Lang & Schwarz at 12:39 CET on Saturday, November 14.
UCB share facts
- Company: UCB S.A.
- ISIN: BE0003739530
- Quote: 296.85 euros on Lang & Schwarz, November 14, 2026, 12:39 CET
European healthcare shares remain sensitive to regulatory decisions and clinical readouts; current market reports are available through current market reports.
